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Abstract Food allergy (FA) is defined as an abnormal
immunological reaction to food proteins. Over 90 % of FAs in
childhood are caused by eight foods: cow’s milk, hen’s egg,
soy, peanuts, tree nuts, wheat, fish and shellfish. The diagnostic
work up for a child with suspected FA includes detailed
medical history, physical examination, FA screening tests and
response to elimination diet and to oral food challenge.
Sometimes additional diagnostic tools to explore intestinal
damage and function could be adopted. Currently, the only
treatment for FA relies on strict elimination diets supervised by
the nutritionist. Main new therapeutic strategies for FA include
allergen-specific (oral, sublingual, epicutaneous, subcutane-
ous immunotherapy and heat treatment of food) and non-
allergen-specific therapies (humanized monoclonal antibod-
ies, anti-IgE and anti-IL5, probiotics). An incorrect diagnosis
is likely to result in unnecessary dietary restrictions, which, if
prolonged, may adversely affect the child’s nutritional status
and growth.
Keywords Cow’s milk allergy  Probiotics 
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Introduction
Food allergy (FA) is a major health issue in western
societies affecting between 5 and 10 % of young children
[1]. During the last decade in the United States pediatric
FA diagnosis rates increased by 18 %, however it has not
been determined whether these findings are related to
increased awareness and reporting. In any case, the use of
specific medical diagnostic codes for FA does represent a
real increase of the disease [2]. It has been estimated that
FA, in the United States alone, accounts for 30,000 emer-
gency room visits and 150 deaths per year [3]. In Italy, the
R. Berni Canani (&)  R. Nocerino  V. Pezzella  L. Leone 
T. Cozzolino  R. Aitoro  L. Paparo  M. Di Costanzo 
L. Cosenza  R. Troncone
Food Allergy Unit, Department of Translational Medicine,
University of Naples ‘‘Federico II’’, Via S. Pansini, 5,
80131 Naples, Italy
e-mail: berni@unina.it
R. Nocerino
e-mail: ritanocerino@alice.it
V. Pezzella
e-mail: cinzia.pezzella@gmail.com
L. Leone
e-mail: ludovicaleone@hotmail.it
T. Cozzolino
e-mail: tom.cozzolino@gmail.com
R. Aitoro
e-mail: aitoro.rosita@libero.it
L. Paparo
e-mail: lorella.paparo@alice.it
M. Di Costanzo
e-mail: mara.dicostanzo@live.it
L. Cosenza
e-mail: lindacosenza@libero.it
R. Troncone
e-mail: troncone@unina.it
R. Berni Canani  R. Troncone
European Laboratory for the Investigation of Food Induced
Diseases, University of Naples ‘‘Federico II’’, Via S. Pansini, 5,
80131 Naples, Italy
123
Curr Pediatr Rep (2013) 1:189–197
DOI 10.1007/s40124-013-0027-3
number of hospital admissions due to food-induced ana-
phylaxis doubled in the last 5 years [4].
Although any food can provoke a reaction, relatively
few foods are responsible for the vast majority of signifi-
cant food-induced allergic reactions in children: cow’s
milk, hen’s egg, soy, wheat, peanuts, tree nuts, fish and
shellfish [2, 5]. Allergy to other foods is increasing too, as
exemplified by reports on sesame and kiwi [6]. There is
also an increasing appreciation of oral allergy syndrome in
children: patients with birch pollen allergy have cross
reactions to heat-labile proteins in various fruits and veg-
etables [7].
Correct diagnosis of FA is important to accurately
establish the prevalence and incidence of this condition and
to ensure appropriate patient care. In fact, FA may have
deleterious effects on family economics, social interac-
tions, school and work attendance, and health-related
quality of life. The diagnostic work-up in a child with FA
includes many steps, but the essential criteria are a thor-
ough medical history-taking and physical examination
together with a clear response to the oral food challenge
(OFC) [8•].
The Multistep Diagnostic Process
Food allergies can be broadly divided into IgE (type I
hypersensitivity)- and non-IgE (usually type IV hypersen-
sitivity)-mediated diseases; or mixed, involving other
immunoglobulins, immune complexes and/or cell-mediated
mechanisms. These differ in clinical presentation, diagnos-
tic testing, and prognosis [8•]. IgE-mediated reactions are
characterized by an acute onset of symptoms generally
within 2 h after ingestion of or exposure to food. IgE-med-
iated reactions to food typically involve the skin, gastroin-
testinal tract, and respiratory tract and may include systemic
reactions (anaphylactic shock). Non-IgE-mediated immu-
nological reactions (e.g., cell-mediated) include food–pro-
tein-induced enterocolitis, proctocolitis, and enteropathy
syndromes. These conditions primarily affect infants or
young children who present with abdominal complaints,
such as vomiting, abdominal cramps, diarrhea, and occa-
sionally blood in the stool and failure to thrive or poor
weight gain. Examples of FA co-morbidities with mixed
IgE- and non-IgE-mediated causes include eosinophilic
gastrointestinal diseases and atopic dermatitis [9]. Table 1
summarizes the main food-induced allergic disorders.
Adverse reactions to food that are not classified as FA
include host-specific metabolic disorders (e.g., lactose
intolerance), a response to a pharmacologically active
component (e.g. an adverse reaction triggered by tyramine
in aged cheeses), or toxins (e.g., food poisoning). Addi-
tionally, psychological (food aversion and anorexia
nervosa) or neurologic (e.g., gustatory rhinorrhea from hot
or spicy foods) responses can mimic FA [10•].
Food allergens may be split into two major classes: class
1, the major food allergens, and class 2, the indirect food
allergens. Class 1 allergens comprise the classical food
allergens to which patients become sensitized by the oral
route or, possibly, through the skin. For these allergens, there
is a clear association between ingestion (or contact) with the
food and the onset of symptoms. Usually the allergens are
heat stable; therefore both uncooked and cooked foods are
problematic. Frequently, more than one organ system is
involved. The primary allergens are highly conserved pro-
teins or carbohydrates present within the pollen and fruits of
a wide variety of plants. They include pathogenesis-related
proteins (PRP), profilins, cross-reactive carbohydrate
determinants (CCD) and lipid transfer proteins (LTP). Class
2 allergens comprise mainly pollen-derived allergens with
cross-reactivity to foods and are often associated with oral
allergy syndrome, sometimes called pollen-FA syndrome.
Most commonly, sensitization is through the respiratory
tract following pollen inhalation. Because class 2 allergens
are usually heat labile and destroyed in the gastrointestinal
tract, symptoms immediately follow eating raw fruit or
vegetables. Examples of class 2 food allergens are latex,
kiwi, apple, peach, hazelnut [10•, 11•].
The evaluation of a child with suspected FA includes: in-
depth patient history, physical examination, screening tests,
response to elimination diet and to OFC (Fig. 1). In children
with multiple FAs, the response to elimination of single
antigens is incomplete, and lengthy assessment with a very
restricted diet is often required. The physician should obtain
a detailed patient history focused on the kind and intake of
symptom-inducing food, the time gap between food inges-
tion and onset of symptoms, reproducibility, presence or
absence of any other symptom-inducing conditions, and the
time of the last symptom. Timing of the first and last
occurrences can reveal whether sensitivity is increasing or
waning. An evaluation of possible cross reactions is helpful
in selected cases. These considerations together with the
quantity necessary to trigger a reaction are helpful for
planning the best procedures to explore the presence of
sensitization to particular foods and to perform OFC as well.
Occasionally, the history can be complicated by the fact that
trace amounts of foods may occur in certain products. The
differential diagnosis could be particularly difficult in sub-
jects with non-IgE-mediated FA where symptoms occur
hours or days later. In addition, in a child with gastroin-
testinal symptoms, the differential diagnosis must also
include: infections, gastrointestinal functional disorders,
celiac disease, brush border enzyme deficiencies, cystic
fibrosis and other primitive forms of pancreatic insuffi-
ciency, inflammatory bowel diseases, anatomical defects
(e.g., pyloric stenosis, malrotation), metabolic disorders
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(e.g., galactosemia), adverse reaction to drugs, and Mun-
chausen syndrome/Munchausen syndrome by proxy.
Antigen-Specific Diagnostic Tests
In Vitro Tests
In vitro tests (determining serum-specific IgE antibodies
against food allergens) are commonly used in the diag-
nostic workup of FA, especially in patients with severe
atopic dermatitis or patients taking antihistamines, where
skin tests are not suitable. Serum IgE levels can be assessed
for crude allergen extracts, individual allergens, or even
allergenic peptides. The results can be a simple qualitative
measurement resulting in a yes or no answer for the
presence of food-specific IgE or alternatively they may
determine a quantitative antibody level [12•]. Measurement
of allergen-specific IgE is performed using the radioaller-
gosorbent test; the detection limit of the system usually is
0.35 kU/L IgE. A subject is considered sensitized if their
specific IgE levels exceed the detection limit. Many clini-
cal studies have been performed to evaluate the reliability
of in vitro testing for food-specific IgE to clinical FA.
Using the ImmunoCAP system, threshold levels of aller-
gen-specific IgE to egg (6 kUa/L), peanut (15 kUa/L), fish
(20 kUa/L), and milk (32 kUa/L) have been shown to
portend positive OFC results with greater than 95 %
accuracy [13•]. Therefore, evaluation of allergen-specific
IgE could possibly obviate the need for potentially life-
threatening reactions to foods during challenge tests. There
Table 1 Main food-induced allergic disorders
IgE-mediated/acute onset
(onset time 30 min up to 2 h)
Non-IgE mediated/delayed onset (onset time
few hours to days)
IgE- or non-IgE mediated/
delayed onset (onset time
few hours to days)
Gastrointestinal tract Oral allergy syndrome;
gastrointestinal anaphylaxis
Dietary protein proctitis, colitis, enterocolitis,
enteropathy; gastroesophageal reflux
disease; food–protein-induced enterocolitis
syndrome; chronic constipation
Eosinophilic esophagitis,
gastroenteropathies
Respiratory tract Rhinitis; conjunctivitis; asthma Chronic pulmonary disease (Heiner
syndrome)
Asthma
Skin Urticaria; angioedema Contact dermatitis Atopic dermatitis
Systemic Anaphylaxis; food-associated,
exercise-induced anaphylaxis
– –
Fig. 1 The diagnostic
algorithm for food allergy. SPT
skin prick test, APT atopy patch
test, ECP eosinophilic cationic
protein, CLP fecal calprotectin,
FA food allergy. *Tissue
damage markers and GI motility
investigations could be used in
patients with gastrointestinal
sings and symptoms possibly
related to FA
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is emerging evidence that component-resolved diagnosis
through measurement of specific IgE to individual, most
often recombinant, food allergens may be superior to
measurements of specific IgE to crude allergen extracts.
For example, clinically relevant peanut allergy seems to
correlate with the detection of specific IgE antibodies to
Ara h 2, a seed storage protein in peanuts [14]. Homolog
seed storage proteins also exist in tree nuts and seeds. In
hazelnut allergies, detection of specific IgE to Cor a 9
suggests a FA that might result in a life-threatening reac-
tion, whereas detection of specific IgE solely to Cor a 1, the
homolog of the birch pollen allergen Bet v 1, suggests a
pollen-associated FA [15]. Similarly, positive specific IgE
to the LTP of hazelnut, Cor a 8, suggests an increased risk
of severe systemic reactions. Similar improvement of the
test performance and diagnostic sensitivity has been seen
when using single kiwifruit allergens compared with the
extract [16].
In IgE-mediated FA, circulating antibodies recognize
specific molecular regions on the antigen surface (epi-
topes), which are classified according to their specific
amino acid sequence (sequential or linear epitopes) or the
folding and configuration of their protein chains (confor-
mational epitopes). Subjects with transient FA produce IgE
antibodies primarily directed at conformational epitopes
(dependent on the protein’s tertiary structure), whereas
those with persistent FA also produce IgE antibodies
against sequential epitopes, which are heat stable [17].
Greater IgE epitope diversity and higher IgE affinity are
associated with more severe FA [18]. In the future, IgE
epitope mapping has the potential to become an additional
tool for the diagnosis/prognosis of FA and lead to a better
understanding of the pathogenesis and tolerance induction
[19].
Some cellular tests, i.e. tests determining the reactivity
of blood cells in vitro (e.g., determination of histamine
release, basophil degranulation, CAST-determination of
sulfidoleukotrienes produced by IL-3 primed basophils
stimulated by allergens in vitro- and flow cytometric
basophil activation test), are increasingly used in selected
tertiary centers with the aim to accurately define their
diagnostic accuracy and standardization. Complementary/
alternative tests (e.g. ALCAT-test, bioresonance, kinesiol-
ogy, leukocytotoxic test, electrodermal tests, iridology and
hair analysis) are quite popular in clinical practice, but
there is absolutely no evidence of their diagnostic value
[20, 21].
In Vivo Tests
Immediate hypersensitivity skin prick tests (SPTs) examine
for the presence of food protein specific IgE. SPTs usually
have sufficient sensitivity and specificity to be the sole
method of skin testing necessary for most clinical scenar-
ios. In general, SPTs have a sensitivity of *90 % but a
specificity of only about 50 % [22]. An important com-
ponent of management is the understanding by clinicians of
the predictive value of individual FA tests. The larger the
size of the wheal on a skin test, the more likely a patient
will react to the food (Table 2) [12, 22, 23]. The quality
and allergen content of the extract employed for the test are
pivotal. Thus, patients with oral allergy syndrome induced
by fresh, but not cooked, tree fruit associated with tree
pollen allergy usually do not show positive tests to com-
mercial extracts. Some studies reported that the SPTs are
positive 40 % of the time with commercial extracts and
81 % of the time using fresh foods. The overall concor-
dance between a positive prick test and a positive challenge
test is 59 % with commercial extracts and 92 % when fresh
foods were used [24]. When a history is positive, and a
commercial food antigen SPT is negative, a prick using
fresh food should be considered.
For non-IgE-mediated disorders, fewer diagnostic tools
exist. Atopy patch tests (APTs) are able to explore cell-
mediate reactions, and they are the most used FA screening
tests in the clinical practice. There is no minimum age for
these tests, which can be performed also in preterm babies
and infants with useful results [9, 25]. APTs have been
proposed for the initial diagnostic approach in children
with suspected non-IgE-mediated CMA and atopic der-
matitis [26], gastrointestinal disorders [26–28] and eosin-
ophilic esophagitis [27]. The use of APTs in the clinical
practice of pediatric gastroenterology could be limited by
subjective interpretation and intra-observer variation.
Recently it has been demonstrated that in children with
gastrointestinal symptoms the diagnostic accuracy of APTs
is influenced by the severity of skin signs [29] and that
APTs could be a valuable tool in the follow-up of pediatric
patients with gastrointestinal symptoms related to non-IgE-
mediated cow’s milk allergy by contributing to the deter-
mination of whether an OFC can safely be undertaken [30].
Table 2 Diagnosis of food allergy with the use of 95 % positive
predictive value (PPV) for specific IgE and skin prick tests
Serum-specific IgE
(U/mL)
Skin prick test wheal
diameter (mm)
Cow’s milk 15 (5 if the child age is
\2 years)
8 (6 if the child age is
\2 years)
Hen’s egg 7 (2 if the child age is
\2 years)
7 (5 if the child age is
\2 years)
Fish 20 7
Peanuts 15 8 (4 if the child age is
\2 years)
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Tissue Damage Markers and Gastrointestinal Motility
Investigations
Several procedures could be adopted in children with gas-
trointestinal symptoms possibly related to FA. These include
endoscopy with histologic evaluation, esophageal pH
monitoring; together with noninvasive tissue damage
markers, such as intestinal permeability, faecal eosinophilic
cationic protein and calprotectin measurement [8, 31].
Although these noninvasive tests would be convenient to
detect an intestinal mucosal reaction to foods, no conclusive
studies are available on the diagnostic accuracy of these
tests, alone or in combination, in the approach to a child with
suspected FA. Patients with allergic eosinophilic esophagitis
or gastroenteritis have peripheral eosinophilia, and children
with severe allergic eosinophilic gastroenteritis might have
anaemia, blood in the stool and decreased serum albumin
and IgG levels. Endoscopy with biopsies are the most
definitive approach and might help in the differential diag-
nosis. Density [15 eosinophils/HPF in the oesophagus is
diagnostic for allergic eosinophilic esophagitis, especially if
the oesophageal pH monitoring is normal and there is lack of
response to high-dose proton pump inhibitors medication
[26]. If food-induced enteropathy or colitis are suspected,
intestinal biopsies revealing primarily eosinophilic infiltra-
tion of the mucosa may be helpful. The mucosal lesions in
FA enteropathies are characteristically focal. Thus, sam-
pling error may result in negative biopsies in a discrete
number of cases. Colonic biopsies are more often helpful in
cases with allergic colitis, usually seen in infants with FA-
induced hematochezia. In children with FA, electrogastro-
graphic evidence of severe gastric dysrythmia and delayed
gastric emptying during OFC have been demonstrated. The
investigations on FA-related motility disorders could be
performed by multichannel intraluminal electrical imped-
ance testing, micromanometric techniques, gastroelec-
trophysiological studies, or measurement of gastric
emptying by 13C-octanoic acid breath test [32].
Oral Food Challenge
Oral food challenge still represents the gold standard for the
diagnosis of FA in order to avoid unjustified diets. When the
food considered for the challenge is still part of the patient’s
diet, a strict elimination diet should be prescribed for at least
2 weeks before the OFC. The optimal duration of elimi-
nation diet before OFC depends mainly on symptom
severity. Different FA-related gastrointestinal diseases need
different durations of elimination diet before OFC: an
elimination of 4–6 weeks is considered adequate for
enterocolitis, proctitis/proctocolitis and enteropathy. How-
ever, for gastroesophageal reflux disease and constipation,
just 2–4 weeks are adequate. The OFC is done by feeding
gradually increasing amounts of the suspected food under
observation by a physician over a period of hours, pro-
tracted for days when no immediate reaction occurs.
Because the procedure carries a small risk of anaphylaxis, it
should be conducted in a supervised medical setting where
resuscitation equipment is available. Several papers have
been published recently on this topic aiming at standard-
izing the procedure [33–35]. The main problems of OFC are
related to the wide variety of symptoms possibly related to
immunological mechanism of FA that lead to difficulties in
the interpretation of results and to the optimal timing and
dosage of this procedure. A rather complex, double-blind-
placebo-controlled food challenge (DBPCFC), routinely
used in research, is recommended in clinical settings only
when patients report entirely subjective symptoms; whereas
an open OFC without placebo is commonly used in children
under the age of 3 years and when objective symptoms are
present [36–38]. Unfortunately, the diagnosis of FA is fre-
quently incomplete, incorrect, or self-reported, and a correct
diagnostic work-up, confirmed by OFC, seems to be
adopted in only a minority of cases [39].
Therapeutic Options
Elimination Diet
Although numerous therapeutic treatment options are cur-
rently being investigated, dietary avoidance remains the
primary treatment for FA [40•]. Inadequate nutritional
status, growth, and dietary intakes have been demonstrated
in children with FA [41]. Altered growth status may be due
to potential loss of nutrients caused by continued allergic
inflammation and/or abnormal intestinal permeability
caused by noncompliance with the diet, unbalanced diet
and additional undiagnosed FA or inappropriate substitute
foods [41]. This highlights the need to make every effort to
optimize nutrition because inadequate nutrient intake may
worsen the risk of lower growth rates in this population.
The elimination diet should be considered carefully
depending on: mechanism of FA; symptoms; nutritional
status; and concomitant factors like food aversive behavior.
A properly managed, well-balanced elimination diet pre-
scribed with the help of certified dietitians, can lead to
resolution of symptoms while maintaining or even opti-
mizing nutritional status.
Critical points in the management of the patient are the
protein:energy ratio and the energy requirements. In fact, the
rate of catch-up growth required (based on the weight for
height or S.D. scores) depends on the individual patients’
current nutritional status, and allergen restrictions. The ideal
protein:energy ratio lies between 8.9 and 11.5 % of total
energy; this ratio could be further increased depending on
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the level of stunting. In addition, for optimal catch-up
growth, 5–10 g/kg/day of protein and 105–126 kcal/kg/day
are commonly required [42].
An often neglected component of treatment is to ensure
patients and/or their caregivers understand the importance
of complete adherence to the diet, as inadvertent con-
sumption of an offending food can prevent resolution of
symptoms and render challenge results useless. As many
FAs of early childhood resolve over time, regular reas-
sessment by the allergist is also important to avoid exten-
ded, unnecessary elimination diets.
Even under the best circumstances, avoidance of aller-
gens is not simple. The variety of commercial food items
available is ever expanding, and ingredients in commercial
products change frequently, requiring consumers to read
product labels each and every time an item is purchased.
Laws that guide the labeling of food allergens vary from
country to country [43]. These laws typically require
identification and disclosure on product labels of those
food components that are considered ‘common food
allergens’ or ‘major allergens’. Healthcare practitioners
and consumers should be aware of their country’s food
allergen labeling laws. When traveling abroad, consumers
with FA should always check the food allergen labeling
laws of their destination country prior to purchasing and
consuming packaged foods [44].
Immunotherapy
The main new therapeutic perspectives for the treatment of
FA include allergen-specific (oral, sublingual, epicutane-
ous, subcutaneous immunotherapy (SCIT) and heat treat-
ment of food) and non-allergen-specific therapies
(humanized monoclonal antibodies, anti-IgE and anti-IL5,
probiotics). Oral food immunotherapy (OIT) is currently
the most investigated approach for persistent FA. This
method is based on the concept that repeated oral/intestinal
exposures to antigens normally lead to tolerance. OIT
protocols usually provide an initial stage with progressive
increase of the dose, followed by a phase of slow accu-
mulation to achieve the desired maintenance dose. Several
studies have demonstrated that OIT with milk is effective
in desensitizing patients with cow’s milk allergy [45, 46].
The aim of the experimental studies of OIT is to develop a
safe protocol that can be used in routine clinical practice.
There is still controversy on OIT, due to concerns for
heterogeneity in protocols, compliance of patients and their
families, failure of desensitization and presence of atopic
disease. Moreover, patients with complicated IgE- and
non-IgE-mediated disease may not respond well to OIT. In
sublingual immunotherapy (SLIT) the food is administered
sublingually, held in the mouth for few minutes, and then
spat or swallowed. Several studies with hazelnut, milk,
peanut, and peach have demonstrated the benefit of SLIT in
increasing the amount of the food tolerated on DBPCFC
[47–49]. Side effects are generally mild, mainly limited to
oropharyngeal symptoms, and rarely require oral antihis-
tamine administration. However, the maximum dose that
can be administered sublingually is limited, which may
limit the maximum dose of food that can be ultimately
tolerated [50•]. Further studies are needed to standardize
the method and demonstrate its safety in larger numbers of
patients. The use of SCIT in persistent FA was quickly
discontinued after reports of fatal reactions with peanut
injections. Consequently, this approach is no longer used
[50•]. In epicutaneous immunotherapy (EIT), patients
receive three 48-h skin patch applications (1 mg of skim-
med milk powder) per week for 3 months [51•]. Adverse
effects are mostly local cutaneous reactions and discomfort
(pruritis and eczema), but don’t include any severe sys-
temic reactions. While EIT appears safe, additional studies
are required to examine efficacy in terms of additional
foods, and what are the maximum doses that can be applied
epicutaneously and tolerated orally [50•]. Omalizumab is a
recombinant humanized monoclonal IgE-blocking anti-
body. It’s an allergen non-specific modality of FA treat-
ment. It decreases or prevents the allergic response
triggered by IgE molecules, binding to the constant
domains of free circulating IgE molecules, reducing IgE-
mediated mast cell and basophil degranulation on allergen
exposure [52•, 53]. Subcutaneous injections of omalizumab
have been shown to have relatively few and tolerable side
effects mainly at the injection site. Less common reactions
included bronchospasm, hypotension, syncope, urticaria,
angioedema and rarely anaphylaxis [54, 55]. Other thera-
peutic strategies with modified allergens (peptides,
sequences of oligodeoxynucleotides, plasmid DNA) have
been evaluated in preclinical studies for the possible
treatment of peanut allergy, but they are currently under-
utilized. It is possible that in the future such studies can be
resumed as a result of a better characterization of antigenic
epitopes responsible for the various forms of FAs.
New Therapeutic Perspectives Deriving
from Immunonutrition
‘‘Immunonutrition’’, a diet-induced immunomodulation, is
becoming an increasingly realistic therapeutic option for
FA. The more promising strategies involve modified anti-
genic peptides and probiotics. Heating cow’s milk and
hen’s egg decreases protein allergenicity by destroying
conformational epitopes. The introduction of extensively
heated milk and egg protein in the diet of subjects with
milk and egg allergy, who tolerate the baked form, is
becoming an alternative approach to induce a faster
acquisition of oral tolerance. Children who incorporated
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baked milk or baked egg into the diet are 16 and 14.6 times
more likely to become tolerant to unheated milk and egg
compared with a comparison group of children who con-
tinued strict avoidance of these foods [56•, 57•].
Recent data strongly suggest that gut microbiota is
important for oral tolerance development [58•]. Adminis-
tration of the probiotic Lactobacillus rhamnosus GG (LGG)
to food-allergic children (age \2 years, challenge-proven
and affected by mild-to-moderate eczema) improved the
eczema score significantly [58•]. Studies in infants with
eczema who received formulas supplemented with LGG
showed benefits in decreasing gastrointestinal symptoms
[59]. For instance, after a challenge study in infants allergic
to cow’s milk proteins, fecal IgA levels were detected to be
higher, and TNF-a levels were lower in the LGG applied
group compared to the placebo [58•]. Nermes et al. [60]
showed a significant decrease in IgA- and IgM-secreting
cells in infants with atopic dermatitis treated with exten-
sively hydrolyzed casein formula (eHCF) supplemented
with LGG, suggesting that this particular probiotic is able to
enhance gut barrier function and accelerate immunological
maturation in infants with FA. Moreover, LGG is able to
induce IFN-c secretion in infants with CMA and in infants
with IgE-associated dermatitis, but not in infants without
CMA [58]. The addition of LGG to an eHCF significantly
improved the recovery of the inflamed colonic mucosa if
compared to that obtained with eHCF alone in infants with
blood in the stool and CMA-induced colitis, as indicated
indirectly by greater decrease in fecal calprotectin and in the
number of infants with persistence of occult blood in stools
after 1 month [61]. We recently demonstrated that an eHCF
containing LGG is able to accelerate the development of
tolerance acquisition in infants with CMA. Infants (aged
1–12 months), consecutively referred for suspected CMA
but still receiving cow’s milk proteins, were invited to
participate in the study. Subjects were randomly allocated
to one of the two groups of dietary interventions: a control
group, who received an eHCF; and an active group, who
received an eHCF containing LGG (at least 1.4 9 107 CFU/
100 mL). After 12 months, the DBPCFC was negative in 15
of 28 control infants (53.6 %) and in 22 of 27 infants
receiving eHCF with LGG (81.5 %, p = 0.027). These
findings suggest an innovative approach for infants affected
by CMA, namely an ‘‘active dietotherapy’’ able to induce a
faster symptom’s remission and to reduce the time of tol-
erance acquisition [62•].
Conclusions
Correct diagnosis of FA is crucial to ensure appropriate
patient care. The essential criterion is a clear response to
elimination diet, and other diagnostic tests are secondary to
this. OFC plays a crucial role in the diagnostic approach to
a child with suspected FA, but it is largely underutilized.
Potential responsible factors contributing to the lack of a
correct diagnostic work-up in the vast majority of cases
could be numerous, and include lack of training on the
procedure, increased reliability on screening methods,
extensive time needed, fear of risk, and suboptimal fee
reimbursement. A comprehensive nutrition assessment
with appropriate intervention is warranted in all children
with FAs to meet nutrient needs and optimize growth.
Frequently an elimination diet is absolutely necessary to
prevent potentially life-threatening food allergic reactions.
However, dietary elimination in FA may also have unde-
sirable consequences. An increasing number of evidences
suggest the role of selected probiotics in prevention or
treatment of FA. These data support the importance of a
‘‘nutritional immunology approach’’ able not only to effi-
ciently cure the symptoms, but also to accelerate tolerance
acquisition in children with FA.
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